bluebird bio, Inc. (BLUE) Shares Bought by Columbus Circle Investors

Columbus Circle Investors increased its position in bluebird bio, Inc. (NASDAQ:BLUE) by 90.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 139,312 shares of the biotechnology company’s stock after acquiring an additional 66,029 shares during the period. Columbus Circle Investors owned approximately 0.30% of bluebird bio worth $19,135,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. QS Investors LLC raised its stake in bluebird bio by 70.7% in the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after acquiring an additional 500 shares during the last quarter. Bank of Montreal Can raised its stake in bluebird bio by 118.9% in the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after acquiring an additional 911 shares during the last quarter. Turner Investments LLC purchased a new position in bluebird bio in the 2nd quarter worth $184,000. SG Americas Securities LLC raised its stake in bluebird bio by 17.9% in the 2nd quarter. SG Americas Securities LLC now owns 1,945 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 295 shares during the last quarter. Finally, Fairfield Bush & CO. purchased a new position in bluebird bio in the 2nd quarter worth $210,000.

TRADEMARK VIOLATION NOTICE: “bluebird bio, Inc. (BLUE) Shares Bought by Columbus Circle Investors” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at https://stocknewstimes.com/2017/11/19/bluebird-bio-inc-blue-shares-bought-by-columbus-circle-investors.html.

In other bluebird bio news, insider Jeffrey T. Walsh sold 35,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $151.38, for a total value of $5,298,300.00. Following the transaction, the insider now directly owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Nick Leschly sold 25,667 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $115.18, for a total transaction of $2,956,325.06. Following the completion of the transaction, the insider now directly owns 339,368 shares in the company, valued at $39,088,406.24. The disclosure for this sale can be found here. Insiders sold a total of 193,168 shares of company stock worth $25,558,003 over the last three months. Corporate insiders own 3.90% of the company’s stock.

bluebird bio, Inc. (NASDAQ BLUE) traded up $3.05 during mid-day trading on Friday, reaching $163.20. The company had a trading volume of 482,407 shares, compared to its average volume of 862,535. bluebird bio, Inc. has a 12 month low of $56.80 and a 12 month high of $164.80.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. During the same quarter in the previous year, the firm posted ($2.07) earnings per share. The company’s quarterly revenue was up 397.4% on a year-over-year basis. equities research analysts anticipate that bluebird bio, Inc. will post -6.68 earnings per share for the current year.

A number of equities analysts recently issued reports on BLUE shares. Evercore ISI started coverage on bluebird bio in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $102.00 target price for the company. Maxim Group restated a “buy” rating and issued a $170.00 target price (up previously from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. Barclays PLC started coverage on bluebird bio in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price for the company. Wedbush restated an “outperform” rating and issued a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a research note on Friday, September 1st. Finally, Leerink Swann reiterated an “outperform” rating and set a $162.00 price objective (up previously from $145.00) on shares of bluebird bio in a research note on Wednesday, November 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the stock. bluebird bio presently has a consensus rating of “Buy” and an average price target of $131.05.

bluebird bio Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply